Phase 1/1b, Multicenter, Open-LabeL, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
NCT #
NCT06040541
Condition(s)
Solid Tumor
Molecular Target(s)
KRAS G12, KRAS G12D, KRAS MUTATION
Drug Classification(s)
Molecular Targeted Therapy, Small Molecule (Targeted)
Agents(s)
RMC-9805
Phase(s)
I
Mechanism of Action
RMC-9805 is a KRAS G12D inhibitor
Purpose
The purpose of this study is to test a new drug called RMC-9805 (the study drug).
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.